JP2021516668A5 - - Google Patents

Info

Publication number
JP2021516668A5
JP2021516668A5 JP2020542989A JP2020542989A JP2021516668A5 JP 2021516668 A5 JP2021516668 A5 JP 2021516668A5 JP 2020542989 A JP2020542989 A JP 2020542989A JP 2020542989 A JP2020542989 A JP 2020542989A JP 2021516668 A5 JP2021516668 A5 JP 2021516668A5
Authority
JP
Japan
Prior art keywords
composition
slamf6
cells
cell population
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020542989A
Other languages
English (en)
Japanese (ja)
Other versions
JP7458318B2 (ja
JP2021516668A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2019/050163 external-priority patent/WO2019155474A1/en
Publication of JP2021516668A publication Critical patent/JP2021516668A/ja
Publication of JP2021516668A5 publication Critical patent/JP2021516668A5/ja
Application granted granted Critical
Publication of JP7458318B2 publication Critical patent/JP7458318B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020542989A 2018-02-12 2019-02-11 癌治療のためのｓｌａｍｆ６スプライスバリアントの調節 Active JP7458318B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862629129P 2018-02-12 2018-02-12
US62/629,129 2018-02-12
PCT/IL2019/050163 WO2019155474A1 (en) 2018-02-12 2019-02-11 Modulation of slamf6 splice variants for cancer therapy

Publications (3)

Publication Number Publication Date
JP2021516668A JP2021516668A (ja) 2021-07-08
JP2021516668A5 true JP2021516668A5 (cg-RX-API-DMAC10.html) 2022-02-21
JP7458318B2 JP7458318B2 (ja) 2024-03-29

Family

ID=67548888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542989A Active JP7458318B2 (ja) 2018-02-12 2019-02-11 癌治療のためのｓｌａｍｆ６スプライスバリアントの調節

Country Status (5)

Country Link
US (1) US11834487B2 (cg-RX-API-DMAC10.html)
EP (1) EP3752252A4 (cg-RX-API-DMAC10.html)
JP (1) JP7458318B2 (cg-RX-API-DMAC10.html)
IL (1) IL276117B2 (cg-RX-API-DMAC10.html)
WO (1) WO2019155474A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms
CN117867107A (zh) * 2023-11-24 2024-04-12 南通大学附属医院 一种构建肠癌诊断和预后相关的甲基化位点的诊断模型方法及其诊断标志物slamf6

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
JP4326944B2 (ja) 2001-07-19 2009-09-09 イネイト・ファーマ ナチュラルキラー細胞活性に関与する表面分子ｎｔｂ−ａ
MXPA04001986A (es) * 2001-08-29 2004-06-07 Genentech Inc Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
JP2005206478A (ja) 2004-01-20 2005-08-04 Kirin Brewery Co Ltd 樹状細胞膜分子−ＩｇＦｃ融合ポリペプチドまたはそれに対する抗体を含む医薬組成物
WO2005124346A1 (en) 2004-05-17 2005-12-29 The Board Of Trustees Of The University Of Illinois 4-1bb receptors are expressed on regulatory t-cells
EP1642905B1 (en) 2004-10-02 2009-01-21 Immatics Biotechnologies GmbH Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
CA2604844A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
WO2007020880A1 (ja) 2005-08-17 2007-02-22 Takara Bio Inc. リンパ球の製造方法
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
TW200823237A (en) 2006-08-28 2008-06-01 Nuvelo Inc Antibodies to NTB-A
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
WO2014161509A1 (en) 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
US10344073B2 (en) * 2014-01-09 2019-07-09 Hadasit Medical Research Services And Development Ltd. Cell compositions and methods for cancer therapy
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms

Similar Documents

Publication Publication Date Title
Samadi et al. Therapeutic applications of mesenchymal stem cells:: a comprehensive review
Fan et al. Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord
Golchin et al. The clinical trials of mesenchymal stem cell therapy in skin diseases: an update and concise review
Chalisserry et al. Therapeutic potential of dental stem cells
Trotzier et al. Fat graft retention: adipose tissue, adipose-derived stem cells, and aging
Vawda et al. Mesenchymal cells in the treatment of spinal cord injury: current & future perspectives
ES2927461T3 (es) Células madre mesenquimatosas derivadas de tejido perinatal: método de preparación y utilizaciones de las mismas
Gugjoo et al. Mesenchymal stem cell research in veterinary medicine
Petrof et al. Cell therapy in dermatology
Conese et al. Paracrine effects and heterogeneity of marrow-derived stem/progenitor cells: relevance for the treatment of respiratory diseases
IL259120A (en) Her2-targeted antigen chimeric receptors2
Farkhad et al. How similar are human mesenchymal stem cells derived from different origins? A review of comparative studies
ES2673861T3 (es) Método novedoso para tratar el daño a la médula espinal utilizando el fragmento de hmgb1
CN103687946A (zh) 用于诱导组织再生的肽及其应用
JP2022522231A5 (cg-RX-API-DMAC10.html)
WO2006113881A2 (en) Method of using stroma cells from cord blood to expand and engraft nucleated cells from cord blood
CN111542597A (zh) 用于扩增造血干细胞和祖细胞的组合物和方法
AR037038A1 (es) Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto
CN115843311A (zh) 高潜能多能干细胞
JP2026063215A5 (cg-RX-API-DMAC10.html)
US20060269526A1 (en) Stromal antigen-presenting cells and use thereof
Su et al. Efficacy of mesenchymal stem cells from human exfoliated deciduous teeth and their derivatives in inflammatory diseases therapy
Rizal et al. Wharton's Jelly Mesenchymal Stem Cells: Differentiation Capacity Showing its Role in Bone Tissue Engineering.
Jain et al. Stem cells research prospects towards precision medicine.
CN111499766A (zh) 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用